As Per the Report, the Size of the Rhinoconjunctivitis Market in the Asia Pacific is valued at USD xx Million in 2020 and is projected to reach USD xx Million by 2025, to grow at a CAGR of xx.x% during the forecast period 2020-2025.
Rhinoconjunctivitis refers to a medical condition that is a combination of rhinitis and conjunctivitis and is one of the most common allergic reactions worldwide. It is an inflammatory disorder that affects nasal and conjunctival mucosa and is caused due to the result of the hypersensitive immune response. Sneezing, watery mucus, itchy nose, and nasal congestion, as well as conjunctivitis which include burning sensation, tears, and redness of eyes are some of the common symptoms of Rhinoconjunctivitis. Poor sleep, irritability and fatigue are also some of the symptoms. According to an article published in the Journal of Allergy and Therapy, allergic rhinitis is one of the most common reasons for hospital visits due to allergies.
Increasing awareness about Rhinoconjunctivitis is expected to be the major growth factor during the forecast period. Also improving medical infrastructure, increasing spending on healthcare and increasing the number of pharmaceutical players involved in R&D in developing nations are expected to boost this industry.
Asia Pacific Rhinoconjunctivitis Market has been segmented and sub-segmented into the following categories
On the basis of region, the Asia Pacific had the largest market and was also the fastest-growing region. Factors like huge population, government initiatives and improving healthcare facilities in countries like China and India are expected to boost the industry in this region.
Top Companies dominating the Asia Pacific Rhinoconjunctivitis Market Profiled in the Report are Johnson & Johnson Inc., Merck & Co., Inc., GlaxoSmithKline, Sanofi Adiga Life Sciences Inc.,
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment
5.1.1 Introduction
5.1.2 Decongestants
5.1.3 Mast-Cell Stabilizers
5.1.4 Antihistamines
5.1.5 Nonsteroidal Anti-Inflammatory Drugs
5.1.6 Intranasal Corticosteroids
5.1.7 Y-o-Y Growth Analysis, By Treatment
5.1.8 Market Attractiveness Analysis, By Treatment
5.1.9 Market Share Analysis, By Treatment
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
6.7 Rest of APAC
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GlaxoSmithKline
8.3 Sanofi
8.4 Merck & Co., Inc.
8.5 HAL Allergy
8.6 Stallergens S.A.
8.7 ALK-Abello A/S
8.8 BioTech Tools s.a.
8.9 Lofarma S.p.A.
8.10 Adiga Life Sciences Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
